Paradigm Biopharmaceuticals Limited
PBIGF
$0.2083
$0.00633.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -10.30M | -24.67M | -39.06M | -42.56M | -46.22M |
| Total Depreciation and Amortization | 95.50K | 96.10K | 96.20K | 97.60K | 99.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 258.60K | 536.90K | 816.20K | 745.30K | 675.60K |
| Change in Net Operating Assets | -5.31M | -5.17M | -5.01M | -5.69M | -6.42M |
| Cash from Operations | -15.26M | -29.20M | -43.15M | -47.40M | -51.87M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 200.00 | 200.00 | -200.00 | -400.00 | -1.00K |
| Cash from Investing | 200.00 | 200.00 | -200.00 | -400.00 | -1.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -109.00K | -105.70K | -102.40K | -101.00K | -99.60K |
| Issuance of Common Stock | 16.00M | 23.06M | 30.12M | 30.26M | 30.40M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -900.00K | -1.37M | -1.84M | -1.80M | -1.76M |
| Cash from Financing | 9.91M | 14.20M | 18.41M | 18.53M | 18.65M |
| Foreign Exchange rate Adjustments | -410.30K | -449.80K | -489.60K | -397.10K | -307.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.76M | -15.45M | -25.24M | -29.27M | -33.53M |